2) tumor specific antigen
肿瘤特异性抗原
1.
Preparation and characterization of nanoliposome-encapsulated tumor specific antigen;
肿瘤特异性抗原纳米脂质体的制备及特性鉴定
2.
Preparation of nanoemulsion-encapsulated tumor specific antigen and study on its character and antitumor immunity;
肿瘤特异性抗原纳米乳剂的制备及抗肿瘤免疫效应
3.
Preparation and antitumor immunity of long circulating Nano-Liposome encapsulated tumor specific antigen
肿瘤特异性抗原长循环纳米脂质体的制备及其抗肿瘤免疫效应
3) tumor-targeting ligands
肿瘤特异性配体
1.
This review describes three kinds of tumor-targeting ligands,including natural tumor-specific ligands,monoclonal antibodies and tumor-homing peptides,used as tumor-targeting moieties.
本文综述了3类用于肿瘤靶向基因治疗载体的肿瘤特异性配体:天然分子、单克隆抗体和靶向性多肽,以及由它们修饰的载体系统用于靶向性肿瘤基因治疗的研究进展。
4) tumor-specific CTL
肿瘤特异性CTL
1.
The cocultural system in vitro (CCS) was used in the present study to induce tumor-specific CTL by IL-18 in order to investigate the effects of various cell components of peripheral blood to prime and enhance the tumor-specific immune responses.
结果表明 ,在肿瘤抗原存在的条件下 ,CCS中rhIL 18能够诱导并促进CTL介导的肿瘤特异性杀伤效应 ;并且 ,在rhIL 18诱导肿瘤特异性CTL的过程中 ,rhIL 18、NK细胞、DC及T细胞均起着十分重要的作用 ,缺少任一组份 ,均对诱导肿瘤特异性CTL有明显差异 (P <0 0 1)。
5) tumor-specific CTLs
肿瘤特异性CTLs
1.
Preparation of tumor-specific CTLs and their therapeutic effects on bone marrow micrometastasis of breast cancer
肿瘤特异性CTLs的制备及其对乳腺癌骨髓微转移的治疗效果
6) Tumor supplied group of factor
恶性肿瘤特异性标志物
补充资料：肿瘤特异性移植抗原
肿瘤特异性移植抗原
又称肿瘤排斥抗原(tumor rejection antigen，TRA)。宿主对这种抗原有免疫反应，企图通过细胞免疫反应控制肿瘤的生长，或作为异己而排斥。大多数人类肿瘤同一组织类型至少有一种共同的TSTA，而且不与其他类型肿瘤反应，有其肿瘤特异性。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条